Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: The Liposome Company TLC D-99

Executive Summary

The Liposome Company TLC D-99: Pfizer returns rights to the liposomal doxorubicin product to TLC on July 14; Pfizer will receive royalties on any sales of the product, which is in Phase III trials in metastatic breast cancer patients as a lower-cardiotoxicity alternative to conventional doxorubicin. TLC is attempting to reinvigorate its pipeline after the failure of its acute respiratory distress syndrome therapy Ventus in a Phase III trial ("The Pink Sheet" June 30, In Brief). TLC has let go of 110 employees, bringing its total headcount to about 300...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel